| Erkrankung: | Brustkrebs (Mammakarzinom) |
| Status der Studie: | Studie rekrutiert |
| Studiendesign: | nicht-interventionell |
| Studienphase: | Phase IV |
| Studienart: | Medikamentöse Therapie |
| Therapielinie: | Erstlinie |
| Haupteinschlusskritieren: | -Patients with a histological diagnosis of advanced/metastatic HR+/HER2- breast Cancer -No prior systemic treatment for advanced/metastatic disease -The treating physician has made the decision to treat the patient - with ribociclib in combination with an aromatase inhibitor in first line, or - endocrine therapy in first line (e.g. letrozole, anastrozol, fulvestrant), or - chemotherapy in first line (e.g. taxanes, capecitabine, with or without bevacizumab) |
| Hauptausschlusskritieren: | -Patients unable to provide written informed consent -Contra-indication according to the respective current German SmPC (“Fachinformation”), as judged by the treating physician - The patient is currently under active treatment in an investigational study (“klinische Prüfung” according to German drug law) |
| Prüfarzt: | Dr. med. Antje Lehnert |